-
公开(公告)号：US20230174511A1
公开(公告)日：2023-06-08
申请号：US17883202
申请日：2022-08-08
Applicant: Viracta Therapeutics, Inc. , Biogen MA Inc.
Inventor： Brian T. HOPKINS , Timothy R. CHAN , Tracy J. JENKINS , Patrick CONLON , Xiongwei CAI , Michael HUMORA , Xianglin SHI , Ross A. MILLER , Andrew THOMPSON
IPC: C07D401/14
CPC classification number: C07D401/14
Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton’s tyrosine kinase and which exhibit desirable characteristics for the same.
-
公开(公告)号：US20190083404A1
公开(公告)日：2019-03-21
申请号：US15527539
申请日：2015-11-19
Applicant: BIOGEN MA INC.
Inventor： Shyam B. Karki , Peter Zawaneh , Cheuk-Yui Leung , Yiqing Lin
IPC: A61K9/20 , A61K31/225 , A61K45/06 , A61K9/28 , A61K9/48
Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a tablet and comprise one or more extended release polymer matrix. Also provided are pharmaceutical compositions in the form of a capsule comprising one or more tablets of the present invention. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
-
公开(公告)号：US20250034590A1
公开(公告)日：2025-01-30
申请号：US18717244
申请日：2022-12-06
Applicant: Biogen MA Inc.
Inventor： Jenny Wang-Yuanzhen Shupe , Alexander Vaca
IPC: C12N15/86
Abstract: The present disclosure pertains to methods for transducing host cells with nucleic acids using an in-line complexer and systems comprising an in-line complexer for transducing host cells. The disclosed methods and systems can be used to produce recombinant adeno-associated virus (rAAV) particles. Also disclosed herein are compositions comprising rAAV particles obtained from the disclosed methods and systems, and uses of the same.
-
公开(公告)号：US20250034150A1
公开(公告)日：2025-01-30
申请号：US18709273
申请日：2022-11-10
Applicant: BIOGEN MA INC.
Inventor： Brian T. Hopkins , Bin Ma , Jürgen Schulz , Marta Nevalainen , TeYu Chen , Robin Prince , Harold George Vandeveer , Isaac Marx , Simone Sciabola , Zain Yousaf
IPC: C07D487/04 , A61K31/437 , A61K31/4985 , A61K31/519 , A61K31/5377 , A61K31/55 , C07D471/04 , C07D519/00
Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables in Formula (I) are as defined herein; and methods for their use and production.
-
公开(公告)号：US20250020660A1
公开(公告)日：2025-01-16
申请号：US18426232
申请日：2024-01-29
Applicant: Biogen MA Inc.
Inventor： Meena Subramanyam , Lakshimi Amaravadi , Eric Wakshull , Frances Lynn , Michael Panzara , Robin McDaid Barbour , Julie Elizabeth Taylor
Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
-
Patent Agency Ranking
公开(公告)号：US20240425573A1
公开(公告)日：2024-12-26
申请号：US18707366
申请日：2022-11-02
Applicant: Biogen MA Inc.
Inventor： Laura Nisenbaum , Tianle Chen , Raj Rajagovindan
Abstract: Provided are methods for treating Alzheimer's disease in a human subject in need thereof comprising administration of an anti-beta-amyloid antibody (e.g., aducanumab) to the subject.
-
公开(公告)号：US12162952B2
公开(公告)日：2024-12-10
申请号：US17050353
申请日：2019-04-25
Applicant: Biogen MA Inc. , Neurimmune AG
Inventor： Jan Grimm , Fabio Montrasio , Isin Dalkilic-Liddle , Mia Marie Rushe , Joseph Walter Arndt
Abstract: Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.
-
公开(公告)号：US20240343733A1
公开(公告)日：2024-10-17
申请号：US18576940
申请日：2022-07-07
Applicant: BIOGEN MA INC. , C4 THRAPEUTICS, INC.
Inventor： Kevin M. Guckian , Emily Anne Peterson , Fang Gao , Ryan Evans , Eric Stefan , Jeremy L. Yap , Corey Don Anderson , Morgan Welzel O'Shea , Jae Young M. Ahn , Christopher G. Nasveschuk , James A. Henderson
IPC: C07D487/04 , A61K31/4545 , A61K31/513 , A61K31/519 , C07D401/14 , C07D471/04 , C07D487/10 , C07D519/00
CPC classification number: C07D487/04 , A61K31/4545 , A61K31/513 , A61K31/519 , C07D401/14 , C07D471/04 , C07D487/10 , C07D519/00
Abstract: This disclosure relates to compounds of Formula (A): IRAK-L-DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.
-
公开(公告)号：US20240327380A1
公开(公告)日：2024-10-03
申请号：US18019540
申请日：2021-08-05
Applicant: BIOGEN MA INC.
Inventor： Brian T. Hopkins , Isaac Marx , Jürgen Schulz , Harold George Vandeveer , Robin Prince , Marta Nevalainen , TeYu Chen , Zain Yousaf , Martin Himmelbauer , Vatee Pattaropong , John Howard Jones , Rab Gilfillan , Edward Yin Shiang Lin , Felix Gonzalez Lopez de Turiso , Bin Ma
IPC: C07D401/14 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/553 , C07D401/12 , C07D403/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/08 , C07D487/10
CPC classification number: C07D401/14 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/553 , C07D401/12 , C07D403/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/08 , C07D487/10
Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.
-
公开(公告)号：US20240216330A1
公开(公告)日：2024-07-04
申请号：US18285123
申请日：2022-04-01
Applicant: BIOGEN MA INC.
Inventor： Michael Joseph Palte , Brian T. Hopkins , Matthew P. Scaramozza , Michael Christian Mingueneau , Alex Pellerin , Chelsea R. Parker Harp , Catherine Barbey
IPC: A61K31/4015 , A61K31/225 , A61K31/4545 , A61K31/4985 , A61K31/506 , A61P25/28 , A61P37/00
CPC classification number: A61K31/4015 , A61K31/225 , A61K31/4545 , A61K31/4985 , A61K31/506 , A61P25/28 , A61P37/00
Abstract: The present disclosure provides combination therapies for treating an autoimmune disease in a subject in need thereof. The methods comprise administering to the subject an effective amount of a BTK inhibitor in combination with an effective amount of a fumaric acid ester (FAE). The autoimmune disease can be treated include, for example, multiple sclerosis (MS), lupus, rheumatoid arthritis (RA), Pemphigus Vugaris (PV), neuromyelitis optica (NMO), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), anti-NMDA receptor encephalitis, or Sjogren's disease.
-
-
-
-
-
-
-
-
-
Search Results
503
records
(took 0.111 seconds)
